Effect of naloxone on endocrine abnormalities in acute renal failure.
Grzeszczak
W
W
Kokot
F
F
Wiecek
A
A
D058186:Acute Kidney Injury / Q000150:complications* / Q000503:physiopathology; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D002116:Calcitonin / Q000378:metabolism; D004700:Endocrine System Diseases / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D010281:Parathyroid Hormone / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D011957:Receptors, Opioid / Q000502:physiology*
D007328:Insulin; D010281:Parathyroid Hormone; D011957:Receptors, Opioid; D007987:Gonadotropin-Releasing Hormone; D009270:Naloxone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D002116:Calcitonin